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During the last decades, erectile dysfunction was considered a direct consequence of aging and, although of a great concern 
for the affected patient, little was available to evaluate and treat this problem. If aging could not be invoked in all cases, than the 
psychogenic etiology was the only explanation. Over the coming years, a better understanding of the physiology involved in the 
penile process of tumescence and detumescence has allowed for better approach of each disease asociated with erectile 
dysfunction so that adequate treatment modalities can be applied to the pacient. As we all know, every pacient is a particular case. 
The development of modern PDE-5 inhibiters, along with other more or less invasive therapies, puts a new light on the medical 
approach of ED. 
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Etiology of ED 
Erectile dysfunction (ED), defined today as the 
constant inability to attain and mantain an erect penis with 
sufficient rigidity for sexual intercourse, has become an 
increasingly common presenting complaint and is 
estimated to 3% of young men with ages between 15 and 
25 years old and 7% of those with age between 25 and 45 
years old suffer from ED, in Romania. This percentage 
increases up to almost 22% of men with ages between 45 
and 55 years old [1]. These numbers are referring to 
secondary ED, which implies the loss of previously normal 
potency. Also, it has been estimated that impotence 




Characteristic  Organic  Psychogenic
Onset  Gradual  Acute
Circumstances  Global  Situational
Course  Constant  Varying
Noncoital erection  Poor  Rigid
Psychosexual problem  Secondary  Long history
Partner problem  Secondary  At onset
Anxiety and fear  Secondary  Primary 
Psychological causes (e.g. depression, anxiety and 
stress involving the workplace) used to be considered 
some time ago as the most common reason for ED [1], 
especially in young men, but are now thought to be the 
primary factor in only a few cases. However,   secondary 
psychological problems are expected in all cases 
associated with ED. 
Despite initial beliefs considering that the vast 
majority of ED cases had a psychogenic etiology, modern 
day’s medicine proved that Organic causes are 
responsible for about 60% to 90% of all causes of ED. 
Most frequent pathologies involved are: 
-  Vasculogenic. The most common single cause, 
due to low blood inflow (e.g. large vessel atherosclerosis). 
The incidence of ED in atheromatous aortoiliac and 
peripheral vascular disease is about 50%. On the other 
side, increased outflow, also known as venous leak or 
venogenic ED, may be responsible. The venous outflow 
regulatory mechanism depends on the completeness of 
trabecular smooth muscle relaxation and the 
expandability of the erectile tissue, defined as the ability 
to achieve maximal corporal volumes at low 
intracavernosal pressures. Arteriogenic and venogenic 
ED can also coexist in the same patient. 
-  Diabetes mellitus is a common cause of organic 
ED, up to 75% of diabetic patients accusing poor 
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erections. It is hypothesized that cavernosal artery 
insufficiency, corporal venoocclusive dysfunction, and/or 
autonomic neuropathy are the major organic 
pathophysiologic mechanisms leading to persistent 
erectile impairment in men with diabetes mellitus. 
-  Endocrinologic disorders are responsible for 
fewer than 5% of instances of ED. The etiologic 
significance of the hypothalamic-pituitary-testicular axis in 
ED is unclear. Their effect on libido and sexual behavior is 
well established, but the effect of androgens on normal 
erectile physiology is poorly understood. It has been 
proved that testosterone enhances sexual interest, 
increases the frequency of sexual acts, and increases the 
frequency of nocturnal erections but has little or no effect 
on fantasy-induced or visually stimulated erections [2]. 
o  Hypogonadotropic hypogonadism is rare, its 
main charachteristic beeing the delayed puberty; 
o  Hypergonadotropic hypogonadism (Klinefelter’s 
syndrome, surgical orchiectomy) may decrease 
libido while potency may persist. 
o  Late onset hypogonadism may lead to ED by 
decreasing the hormonal levels in a patient who 
previously had a normal androgenic function. 
o  Hyperprolactinemia (pituitary adenoma, 
craniopharyngioma, drugs) is associated with 
low or low-normal levels of serum testosterone, 
its effects on erectile function appear to be 
centrally mediated. Hyperthyroidism is commonly 
associated with diminished libido and, less 
frequently with ED, while ED associated with 
hypothyroid states has been reported and may 
be secondary to associated low levels of 
testosterone secretion and elevated levels of 
prolactin. 
-  Renal failure: Approximately 50% of dialysis-
dependent uremic patients suffer from ED, but 
improvement after transplantation occurs in many patients 
mostly because of reversal of the anemia associated with 
chronic renal failure and improvement in uremic 
neuropathy. In this case, the psychogenic etiology cannot 
be neglected 
-  Neurogenic. It is estimated that 10-19% of the 
organic ED are neurogenic [3]. The main causes are: 
o  intracerebral (Parkinson’s Disease, 
cerebrovascular disease – especially efferent 
pathways from the medial preoptic area may be  
affected in addition to higher cortical functions, 
affecting sexual response; other causes are: 
stroke, encephalitis, or temporal lobe epilepsy) 
o  spinal cord (trauma - psychogenic erections are 
not possible in patients with complete lesions 
above T12; up to 75% of patients with multiple 
sclerosis have sexual disfunction; 
myelodysplasia).  
o  peripheral nerves are also affected in alcoholic 
neuropathy, diabetic neuropathy (most common 
cause), after surgery (radical pelvic surgery) and 
trauma. 
-  Trauma: pelvic fractures with ruptured posterior 
urethra. The damage to the neurovascular bundle or to 
the internal pudendal or common penile artery at the time 
of injury is predominantly responsible for most of the ED 
seen following these injuries. Perineal trauma, considered 
as a “hidden” cause of ED, is often considered to be 
psychogenic, but neurovascular lesions may occur. 
Bicycle accidents and extensive bicycle riding account for 
a significant portion of these blunt perineal injuries, most 
of them during childhood. 
-  Penile diseases: vascular lesions in priapism, 
Peyronie’s disease or other traumatic lesions of tunica 
albuginea or congenital deformities, can cause ED. 
-  Malignant diseases: lower abdomen or pelvic 
organs malignancies may cause organic ED. However, in 
the vast majority of malignancies, the psychogenic 
etyology is considered the most important. 
-  Iatrogenic: consists in aortic or peripheral 
vascular surgery, renal transplantation (especially if a 
second contralateral transplantation is performed with 
end-to-end hypogastric artery anastomosis), perineal 
irradiaton (leads to fibrosis of cavernosal erectile tissue), 
cavernosal spongiosal shunts performed for the 
emergency treatment of priapism, abdominal perineal 
resection of the rectum, radical prostatectomy or 
cystoprostatectomy (the incidence of ED can be lowered 
to 40% – 60% if nerve sparring techniques are used), 
transurethral sphincterotomy (should avoid incision at the 
3 o'clock and 9 o'clock positions to prevent thermal injury 
to the cavernosal arteries). Other procedures may cause 
psychogenic ED. 
Drugs: Medications inducing impotence can 
constitute up to 25% [4] of all cases. Patients taking 
medications affecting the autonomic nervous system or 
cardiovascular system may benefit from change or modify 
these medications, but attention must be paid to the risks 
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Treatment 
Nowadays, the treatment for ED offers many more or 
less invasive options. If the diagnostic algorithm 
diagnosed a primary cause, the treatment will aim to 
eliminate the cause, hoping that ED will disappear 
subsequently. Despite the continual evolution of medicine, 
in most cases specific therapy for ED is still necessary, 
ranging from minor life-style changes to complex vascular 
surgery. 
Non surgical therapy includes: 
1.  Psychological therapy, especially sex therapy 
is recommended for the patients with evidence of 
psychogenic ED and no detectable organic 
cause. A short course (4 to 12 weeks) of sex 
therapy should be prescribed. Family planning 
may also help fighting ED, if the cause is 
somehow interconnected [5]. 
2.  Lifestyle changes, when ED is linked with 
obesity, initial stages of diabetes mellitus, etc. 
There is some evidence that ED may 
spontaneously subside if the general health 
status of the patient improves. 
3.  Medication Change – if ED is caused by 
medications.  
4.  Herbal or vitamin supplements are being used 
for centuries in treating ED, and they still have 
some role. Although some studies suggest that 
there is a high rate of placebo responders, 
herbal supplements are clinically proved to 
improve sexual function [6]. 
5.  Pelvic floor exercises may reduce ED, 
although there is only limited evidence 
supporting that theory [7]. 
6.  Hormonal therapy, more specific testosterone 
replacement, is proved as very effective if the 
cause of ED is the low level of testosterone. 
Some authors suggest that the testosterone level 
should be checked in all patients presenting for 
ED [8]. However, if low testosterone is 
diagnosed, further testing is necessary to rule 
out a metabolic syndrome. Nowadays, 
testosterone is available in several presentation, 
including patches, gels, pellet, oral pills, and 
buccal agents. The literature suggests that the 
results are similar, regardless the way of 
administration. The only major issue seems to be 
the correct indication for testosterone 
suppression. 
Recent evolutions developed a preparation of 
dihydrotestosterone, promising better results in 
hypogonadal men with a propensity to 
gynecomastia or boys with constitutionally 
delayed puberty [9]. 
Dehydroepiandrosterone has a controversial role 
in improving the treatment of ED, although some 
data may suggest improvement of sexual 
function in treated men [10]. 
Human Chorionic Gonadotropin proved effective 
when administered to aged men with 
testosterone levels in the lower range of normal. 
The results included a decrease in fat mass, an 
increase in body mass and no effect on muscle 
strength [11]. 
7.  Oral therapy – phosphodiesterase type-5 
inhibitors (PDE-5) 
  
Since 1998, when sildenafil citrate (Viagra) was 
introduced, the management of men with ED has 
revolutionized. Sildenafil increases the effects of the blood 
pressure lowering medications of nitrates, e.g. isosorbide 
dinitrate (Isordil), isosorbide mononitrate (Imdur, Ismo, 
Monoket), nitroglycerin (Nitro-Dur, Transderm-Nitro) that 
are used primarily for treating angina. Sildenafil increased 
the number of patients using other therapeutic modalities 
such as intracavernosal injections and penile prostheses. 
The drug blocks the hydrolysis of cyclic GMP, enhancing 
the accumulation of cyclic GMP and potentiating the 
relaxant effects of nitric oxide. Sildenafil is effective in 
treating ED resulting from a variety of organic causes, 
including diabetes mellitus. Sildenafil is contraindicated in 
patients who require nitroglycerine to treat myocardial 
ischemia. Since then, new PDE-5 inhibiters were 
developed, each promising to be faster, better or longer 
acting than the original. 
Tadalafil (Cialis) is also a new, potent and selective 
PDE5 inhibitor, it’s most unique and identifying 
characteristic being its long half-life of 17.5 hours, 
compared with 4 hours for sildenafil (Viagra) and 
vardenafil (Levitra) [12]. Tadalafil is a safe, well-tolerated, 
and efficient treatment for all severities and etiologies of 
ED, and its long half-life lends itself to a longer 
therapeutic window with on-demand dosing and effective 
steady-state plasma concentrations with once-daily 
dosing. 
Tadalafil may also improve lower urinary tract 
symptoms in men with benign prostatic hyperplasia 
(BPH). Researchers from Nashville, Dallas, San Antonio 
and Indianapolis presented these findings during the 
104th Annual Scientific Meeting of the American 
Urological Association (AUA). In this study [13], 
researchers randomly separated 200 men, with an age 
equal to or older than 40 years and at least a six month 
diagnosis of BPH-LUTS with an International Prostate 
Symptom Score (IPPS) greater than or equal to 13, into 
two groups taking either 20 mg of tadalafil once daily or a 
placebo. After 12 weeks of treatment, the men taking 
tadalafil experienced improved detrusor pressure at 
urinary flow rate, peak flow rate (Qmax), bladder capacity, 
post-void residual volume and bladder voiding efficiency. 
Relative symptom improvement in the IPSS also was 
significantly better in the tadalafil group. At the end of the 
study, the proportion of obstructed patients in the placebo Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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group increased, while the proportion in the tadalafil group 
decreased [14]. 
Vardenafil (Levitra) is a potent and selective PDE5 
inhibitor. Data showed [15] that 38.9% preferred 
vardenafil compared to 34.5% sildenafil (26.6% had no 
preference). Vardenafil was significantly superior to 
sildenafil in terms of erectile function, intercourse 
satisfaction and overall satisfaction. There were also a 
significant higher percentage of positive responses for 
vardenafil with regards to erection hardness for 
penetration, maintenance of erection, maintenance until 
completion, and erection confidence. 
Long-term use of Vardenafil (Levitra) at the maximum 
recommended dosage does not adversely affect sperm 
concentration, total sperm count per ejaculate, or sperm 
morphology or motility, a study recently found [16]. 
Because recent data suggest that many men in their 
reproductive years now use phosphodiesterase-5 (PDE-5) 
inhibitors for erectile dysfunction (ED), Keith Jarvi, 
professor of surgery at the University of Toronto and his 
colleagues examined the long-term effects of these 
agents on sperm concentration and other semen 
characteristics. They compared the effects of vardenafil 
(20 mg), sildenafil (Viagra, at 100 mg), and placebo in 200 
men aged 25-64 years (mean age 39 years). Some men 
did not have ED and the others had ED but were able to 
produce semen samples without ED therapy. Following 
an unmedicated screening period of four weeks, each 
subject underwent daily treatment with vardenafil, 
sildenafil, or placebo for six months. After the treatment 
phase, men with abnormal semen analyses also 
participated in a three-month follow-up. The primary 
variable was the proportion of subjects treated with 
vardenafil who had a 50% or greater reduction in mean 
sperm concentration from baseline to six-month last 
observation carried forward (LOCF), compared with 
placebo-treated men. An analysis of the mean changes 
from baseline to six-month LOCF revealed that sperm 
concentration was 2 million/mL for vardenafil, 8 million/mL 
for sildenafil, and 1 million/mL for placebo. The 
percentage change of normal sperm morphology was -1% 
for vardenafil, -1% for sildenafil, and 0% for placebo. The 
change in total sperm motility was similar for vardenafil, 
sildenafil, and placebo. The researchers observed no 
statistically significant difference in the median changes in 
total sperm count per ejaculate (millions) for men taking 
vardenafil, sildenafil, or placebo. 
The current recommendations in medical treatment of 
ED is that all three PDE-5 inhibitors should be tried (one 
at a time), before shifting to more invasive therapy [15]. 
 
8.  Intracavernous injection – although long known 
and used since the initial demonstration of 
Brindley in 1983, it is in constant evolution and 
development. Most commonly used are 
papaverine (alkaloid isolated from opium), 
phemtolamine and alprostadil (widely known as 
Caverject). Some authors report good results 
when using combination of two or three agents 
[16]. 
9.  Intraurethral Therapy proved effective in treating 
ED during the last decades. The MUSE device, 
containing alprostadil, is the only FDA approved 
treatment. 
10.  Vacuum Erection Device (VED) is one of the 
most common choices of noninvasive therapy for 
ED. It consists of a cylindrical component and a 
suction device that the patient places around the 
penis to create negative pressure and achieve 
an erection. Maintenance of erection is then 
accomplished with an elastic constriction ring 
placed at the base of the penis. Patients with 
significant peripheral vascular disease, those 
receiving anticoagulants, and diabetics are 
generally not good candidates for the VED. 
Patient acceptance and satisfaction with VED in 
all types of ED (including diabetic ED), have 
been reported to be 68% to 83%, while the most 
frequent complications remain difficulty with 
ejaculation, penile pain, ecchymoses, 
hematomas, and petechiae (patients taking 
aspirin or warfarin are more likely to develop 
complications related to vascular fragility). 
Vacuum erection devices (VED), because of 
their ability to draw blood into the penis 
regardless of nerve disturbance, have become 
the centerpiece of penile rehabilitation protocols. 
Even nerve-sparing radical prostatectomy 
damages the cavernous nerves and leads to 
temporary erectile dysfunction (ED) in men 
recovering from prostate cancer surgery. 
Historically, patients recovering from prostate 
cancer surgery have been advised that the 
return of erectile function (EF) can take from 6 to 
18 months, or even longer. Recently, there has 
been a growing movement to proactively treat 
patients postoperatively for presumed nerve 
damage to stimulate nerve recovery and possibly 
reduce the degree of irreversible damage [17]. 
 
Surgical techniques used in the treatment of ED 
aim to restore erection by means of intracavernous 
prosthesis or to cure other cause that led to ED. 
1.  Penile prostheses are represented by several 
constructive models: semirigid rod, positionable, 
two piece inflatable or three piece inflatable. 
Although the cost and high invasiveness of the 
procedure may reduce its expansion in the 
general population, the results are generally 
better, in terms of errection, personal and partner 
satisfaction. Future evolutions will most likely try 
to improve the long term mechanical reliability 
[18]. Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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2.  Vascular surgery for ED became widespread at 
the  end of the 1980s, but the poor long term 
results have somehow compromised the initial 
enthusiasm. The American Urological 
Association Guidelines still considers this type of 
intervention as experimental, due to the lack of 
consistent data and standardized procedures 
[19]. The main procedures used today are penile 
revascularization and penile venous surgery, 
recommended only for selected patients and 
offering fair long-term results. 
Future developments 
Erectile dysfunction grew, in less than two decades, 
from a border-line disease approached by some 
specialists, to a specialty by itself, a multi-billion dollar 
business or a field of continuous research. The evolution 
is far from being over, and many new spectacular 
evolutions are more than likely. From minor improvements 
in current treatments to breakthrough new therapies, 
erectile dysfunction has still many to offer [20]. 
An innovative drug-delivery system known as 
nanoparticles encapsulating nitric oxide and prescription 
drugs looks promising for topical treatment of ED, 
according to a new study by scientists at Albert Einstein 
College of Medicine of Yeshiva University [21]. The new 
system, tested successfully on a small number of animals, 
could potentially prevent side effects associated with oral 
ED medications, if study results can be replicated in 
humans. That could mean safer and more effective ED 
therapy for millions of men with heart disease and other 
health problems affecting erectile function. The study is 
published recently in the online edition of the Journal of 
Sexual Medicine, September 2009 [21]. 
The drug-delivery system, developed by Einstein 
scientists, consists of nanoparticles, each smaller than a 
grain of pollen that can carry tiny payloads of various 
drugs or other medically useful substances and release 
them in a controlled and sustained manner. An effective 
topical therapy could be especially significant for those 
ED patients particularly men with diabetes who have 
reduced levels of nitric oxide (NO), the signaling molecule 
that dilates blood vessels responsible for erectile activity. 
These men, who often aren't helped by oral PDE5 
inhibitor drugs, may benefit from direct application of NO 
or the PDE5 inhibitors. Five of the seven rats treated with 
the NO-containing nanoparticles, and all 11 rats treated 
with nanoparticles encapsulating NO plus sialorphin or 
tadalafil showed significantly improved erectile function. 
None of the seven rats in a control group, which received 
empty nanoparticles, showed any improvement. "The 
response time to the nanoparticles was very short, just a 
few minutes, which is basically what people want in an ED 
medication," adds Dr. Davies. "In both rats and humans, it 
can take 30 minutes to one hour for oral ED medications 
to take effect” 
VIVUS, a pharmaceutical company dedicated to the 
development and commercialization of novel therapeutic 
products, today announced it has initiated a second 
pivotal Phase 3 clinical trial of avanafil, its investigational 
new drug for the treatment of erectile dysfunction (ED). 
Avanafil is a next-generation, fast-acting, selective, 
investigational oral phosphodiesterase type 5 inhibitor. 
The study, REVIVE-Diabetes (TA-302), is a multicenter, 
randomized, double-blind, placebo-controlled trial and will 
evaluate the safety and efficacy of avanafil in the 
treatment of ED in men with type 1 or type 2 diabetes. 
Subjects who meet the inclusion criteria will undergo a 
four-week non-treatment run-in period followed by 12 
weeks of treatment. The co-primary endpoints of the 
study will be the improvement in the erectile function as 
measured by changes in the sexual encounter profile 
(SEP) questions 2 and 3, and improvement in erectile 
function as measured by the erectile function domain 
score of the International Index of Erectile Function (IIEF) 
[22]. The SEP is a self-administered patient diary and the 
IIEF is a patient questionnaire; both are used as standard 
diagnostic tools to assess erectile dysfunction. REVIVE-
Diabetes is the second of three planned pivotal studies in 
the avanafil Phase 3 development program. 
ZoraxelTM is being developed as an orally 
administered, on-demand tablet. It has a well established 
and excellent safety record in humans and appears to 
lack severe side effects associated with standard of care 
PDE-5 inhibitor ED drugs, such as priapism, severe 
hypotension, myocardial infarction, sudden death, 
increased intraocular pressure and sudden hearing loss. 
ZoraxelTM is a centrally acting, dual enhancer of 
neurotransmitters in the brain, whereas PDE-5 inhibitors 
only target end organ erectile function and work in 
peripheral blood vessels. In preclinical animal models, 
ZoraxelTM has significantly improved all three functions of 
sexual activity, i.e. sexual arousal, erection, and release, 
and may be a more effective ED treatment for patients 
who are responsive or unresponsive to PDE-5 inhibitors. 
The Zoraxel Phase IIa trial is a double blind, placebo-
controlled, dose ranging study conducted at three U.S. 
study sites in up to 40 male subjects ages 18 to 65 with 
ED for six months. Main study endpoints for the 8-week 
treatment period were the Sexual Encounter Profile (SEP) 
and the International Index of Erectile Function (IIEF), 
both of which are validated surveys for assessing erectile 
function. Planning is underway for initiation of Phase IIb 
clinical studies. 
Momentary Squeeze (MS) Pump (by AMS) was first 
introduced nearly two years ago, and Dr. Eid has 
implanted it with great success in patients suited to the 
CX-cylinder and LGX-cylinder versions. (The LGX model 
offers the potential for increased penile length in patients 
complaining of penile shortening after radical 
prostatectomy.) Both cylinders now feature redesigned 
proximal ends. At only 9.5mm in diameter, the ends allow Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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for significantly easier insertion for patients with fibrotic 
proximal corporal bodies. 
The MS Pump's advantages include a smaller profile 
(which enables a more discreet placement) and one-touch 
deflation. However, this quality can result in operational 
difficulties with inflation (more difficult to get a hold of 
within the scrotum) and deflation (small button can initially 
be difficult to find). In addition, its new lockout valve has 
the advantage of preventing auto-inflation (potentially 
embarrassing and/or painful), but can at times make it 
difficult to initiate inflation. For these reasons, Dr. Eid 
recommends this pump for the younger patient with an 
average-sized penis.  
Tactile Pump (700 CX Series by AMS "The AMS 
700 CX Series with the Tactile Pump remains my 
prosthesis of choice for the older patient where pump 
concealment is not an issue," says Dr. Eid. "This pump is 
large, easily palpable, remains the softest to inflate and 
has a very large deflation footprint, which is quickly 
recognized by the patient."  
Titan Pump – Coloplast. The FDA approved the 
improvements to the pump component of the Coloplast 
Titan prosthesis in July 2008. Although the cylinders and 
reservoir remain the same as the previous model, the 
pump now features a one-touch-release (OTR) deflation 
valve -- easy for patients to locate and operable with one 
hand. In addition, the pump offers a non-bulky, low-profile 
size; enhanced silicone for higher threshold "tear 
strength" (likely to result in increased product durability, 
an issue with previous versions); and an overall simplicity 
likely to decrease repeat office visits, phone calls, and 
repeat training time. From a hospital standpoint, 
intraoperative prep of the device provides for easier 
priming of the implant system (the removal of excess air 
prior to filling) and may reduce slightly the overall 
intraoperative time.  
In a recent study ("Evaluation of Three Penile 
Prosthesis Pump Designs in a Blinded Survey of 
Practitioners," Urologic Nursing, 2008), 32 medical 
professionals, all familiar in teaching the operation of 
penile implants to patients, reviewed currently available 
penile pumps. The blindfolded reviewers, examining the 
pumps under time constraints through mock scrotal sacs, 
were asked to rate device: 
- ease of location of deflation valve 
- ease of inflation 
- ease of deflation, and 
- anticipated ability to train patients in clinical 
setting.  
The well known PDE-5 inhibitors may soon live a 
second youth, after new talents of their molecules are  
being revealed. Sildenafil citrate, more widely known as 
Viagra, has already been shown to improve heart function 
and may one day have value in either treating or 
preventing heart damage due to chronic high blood 
pressure [23]. The key, investigators say, is sildenafil's 
effects on a single protein, RGS2, newly identified in the 
latest study as an essential link in the chain reactions that 
initially protect the body's main blood-pumping organ from 
spiraling into heart failure. Experimenting in mice, the 
team of heart experts first established that after a week of 
induced high blood pressure, the hearts of animals 
engineered to lack RGS2, or regulator of G-protein 
signaling 2, quickly expanded in weight by 90 percent. 
Almost half the mice died of heart failure. In mice with 
RGS2, by contrast, the dangerous muscle expansion, 
known as hypertrophy, was delayed, growing only 30 
percent, and no mice died [24]. Subsequent tests treating 
hypertensive mice that had RGS2 with sildenafil showed 
enhanced buffering, with less hypertrophy, stronger heart 
muscle contraction and relaxation, and as much as 10 
times lower stress-related enzyme activity compared to 
their untreated counterparts. In mice lacking RGS2, 
sildenafil had no effect [25]. 
Centraly acting drugs, such as yohimbine, 
trazodone or apomorphine may replace at some point the 
PDE-5 inhibitors. Yohimbine hydrochloride is an 
adrenergic antagonist, acting centrally; its effect is to 
increase cholinergic and decrease adrenergic activity. 
Yohimbine also acts as a mood stimulant. Its efficacy rate 
is only about 20% to 25% overall, and it seems to be most 
effective in patients with psychogenic ED. Trazodone, 
already known for its antidepressant effect, showed some 
effect in improving erections, despite several side effects. 
Apomorphine existed for a while on the market as ED 
therapy, but some issues concerning the way of 
administration limited very much its success. Future 
evolutions will most likely overcome this downside, putting 
in a new light the centrally acting drugs [26]. 
Melanocortin Receptor Agonists are used is 
controlling food intake and energy expenditure, but also 
proved promising in modulating erectile function and 
sexual behavior [27]. 
The end of 2006 was marked by the first clinical trial 
on humans, using gene therapy for treating ED. The 
results suggest that gene therapy lasts for months, 
eliminating the needs for on-demand therapy, opening the 
door towards the future of treatment for ED. The authors 
of the study are making several comments regarding 
possible complications and side effects of gene therapy, 
but also challenging results and possible ways of 
development [26]. 
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